#vertex-pharmaceuticals

#vertex-pharmaceuticals

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

On that sunny March morning, in a small health center in Lobamba, a rural area of Eswatini, this 32-year-old sex worker has just become one of the first people in the world to receive lenacapavir, a drug that, administered twice a year, offers nearly 100% protection against HIV.

The INLIGHT interim readout reported a 14.3% placebo-adjusted reduction in visceral fat six months after a single dose, alongside preservation of lean muscle mass - a differentiated profile compared to GLP-1 therapies that often reduce muscle alongside fat.

We are continuing to execute our prediction markets treasury strategy, and we are pleased that Lind provided us with substantial capital, stated Shai Novik, Executive Chairman of Enlivex.

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, confirming its commitment to advancing healthcare and life sciences.

Guggenheim analyst Seamus Fernandez raised his firm's price target on AstraZeneca to 16,500 GBp from 16,000 GBp, maintaining a Buy rating after updating the firm's model ahead of Q1 earnings.

RBC Capital analyst Luca Issi upgraded the stock to Outperform from Sector Perform with a price target of $35, up from $11. Wells Fargo also upgraded uniQure to Overweight from Equal Weight with a $60 price target. The catalyst: the departure of Vinay Prasad from the FDA. RBC views this as a positive for uniQure, noting it is "not inconceivable" that the FDA reverts to its prior stance, and believes Prasad's departure is likely to open up a more balanced discussion on risk/reward for Huntington's disease.

I went to ChatGPT and came up with a plan on how to do this. He also used AlphaFold, an AI tool from Google's DeepMind, to find mutated proteins that could be potential targets for treatment. While an immunotherapy treatment that looked like a good fit for Rosie was identified, the drugmaker wouldn't provide it.

Some 1 million patients in the U.S. live with a type of heart disease called heart failure with preserved ejection fraction, or HFpEF, caused by a stiffening of a chamber of the heart that makes it much more challenging to distribute blood throughout the body. The condition has few approved therapies and high mortality rates.

The Stanley Family Foundation announced another $280 million for the Stanley Center for Psychiatric Research at Broad Institute earlier this month, bringing its total contributions to the Massachusetts-based nonprofit over $1 billion.

X4 Pharmaceuticals drew a fresh initiation from Guggenheim, which assigned a Buy rating and $12 price target, framing the company as a "differentiated hematology play" with significant upside in the next 18 months. The firm's thesis centers on mavorixafor, a potential first-in-class oral CXCR4 antagonist already approved for WHIM syndrome and currently in Phase 3 development for primary chronic neutropenia.

According to the patent, a specific crystalline form of the drug known as polymorph C may be more effective than other versions because it is absorbed more efficiently by the body. The patent also notes that laboratory studies showed the drug reduced tumor growth and helped mice with brain tumors live longer, prompting early clinical trials to test whether the treatment is safe and effective in humans.

The news is the latest sign of the FDA's heightened scrutiny of vaccines under Health Secretary Robert F. Kennedy Jr., particularly those using mRNA technology, which he has criticized before and after becoming the nation's top health official. Moderna received what's called a "refusal-to-file" letter from the FDA that objected to how it conducted a 40,000-person clinical trial comparing its new vaccine to one of the standard flu shots used today.

Laboratories turned to a smart workaround when COVID‑19 testing kits became scarce in 2020. They mixed samples from several patients and ran a single test. If the test came back negative, everyone in it was cleared at once. If it was positive, follow-up tests would zero in on who was infected. That strategy, known as group testing, saved valuable time, money, and resources.

Bristol Myers' Growth Portfolio surged 16% to $7.4 billion in Q4, demonstrating the company's successful product diversification strategy. Key contributors included Opdivo at $2.69 billion (+9%), Eliquis at $3.45 billion (+8%), and standout performers Breyanzi at $392 million (+49%) and Camzyos at $353 million (+59%). However, the Legacy Portfolio declined 15% to $5.1 billion as generic competition intensified. Revlimid plummeted 55%, while Sprycel dropped 60%, reflecting the patent cliff challenges facing the company.

EMPAVELI is the first and only approved treatment for C3G and IC-MPGN across pediatric patients 12+, adults, and post-transplant recurrence. That's roughly 5,000 patients in the U.S., with EMPAVELI holding exclusive approval for about two-thirds. Add the European CHMP positive opinion in December 2025, and you have a rare disease franchise with global expansion potential and pricing power that typically commands gross margins north of 90%.

Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a rare genetic disorder primarily affecting boys, caused by a deficiency in the enzyme needed to break down sugar molecules. This harmful buildup in cells and tissues impacts multiple body systems, causing frequent infections, organ enlargement and developmental disabilities. Management involves supportive care and enzyme replacement therapy, as there is currently no cure,

We provide thought partnership. When a company is developing a drug, there's a lot of work involved, such as understanding the science, designing a study and generating good data. We come in and explain what the standard of care looks like today for their patient population, and what we think it will look like in five to eight years or whenever they plan to launch their therapy.

The cancer was fastacting, and if I'd left it even six months, the outcome could have been much worse,

Eduardo Vilar-Sanchez has spent more than 10 years pursuing a goal that seemed very distant, but which he now sees as a little closer: to develop a preventive vaccine against cancer. The physician and researcher is leading a study that presented the first promising results of a colon cancer vaccine in a small group of patients suffering from a rare disease that makes them 17 times more likely to develop colon cancer than the general population.

For families living with neurodegenerative disease, the hardest part is not always the diagnosis. It is the slow erosion that follows: memory fading, personality shifting, independence shrinking. It unfolds quietly. First, forgotten appointments. Then repeated questions. Then moments when a familiar face no longer feels familiar. The illness does not isolate itself to one body. It rearranges the lives around it.

After leading Pfizer through the frantic race to develop the first FDA-approved COVID-19 vaccine, CEO Albert Bourla has set his sights on a new, arguably more difficult moonshot. "We saved the world from Covid, now we'll save the world from cancer," Bourla told Fortune Editor-in-Chief Alyson Shontell, outlining the company's massive pivot toward oncology following the pandemic. This ambition is backed by a historic reallocation of capital.